{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:22:56Z","timestamp":1754144576973,"version":"3.41.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.urolonc.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T23:13:37Z","timestamp":1740698017000},"page":"467.e13-467.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of metabolic syndrome and chronic kidney disease with nonmuscle invasive bladder cancer recurrence and progression"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2274-1472","authenticated-orcid":false,"given":"Christabel","family":"Egemba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipen J.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gonzalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad R.","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6 Suppl 1","key":"10.1016\/j.urolonc.2025.02.008_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology staging and grading and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.008_bib0002","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11255-016-1264-5","article-title":"Chronic kidney disease as an important risk factor for tumor recurrences progression and overall survival in primary non-muscle-invasive bladder cancer","volume":"48","author":"Li","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.008_bib0003","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2014.05.009","article-title":"Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression\u2013introducing a novel prognostic model for bladder cancer recurrence","volume":"32","author":"Rausch","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.008_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta T1 and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"162","key":"10.1016\/j.urolonc.2025.02.008_bib0005","first-page":"524","article-title":"EORTC risk tables\u2013a new diagnostic tool in urology","volume":"27","author":"Bobi\u0144ski","year":"2009","journal-title":"Pol Merkur Lek Organ Pol Tow Lek"},{"issue":"4","key":"10.1016\/j.urolonc.2025.02.008_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.008_bib0007","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.canep.2011.02.014","article-title":"Diabetes and urothelial cancer risk: the Multiethnic Cohort study","volume":"35","author":"Woolcott","year":"2011","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.008_bib0008","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/1097-0142(19940315)73:6<1708::AID-CNCR2820730626>3.0.CO;2-J","article-title":"Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate","volume":"73","author":"Thrasher","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2025.02.008_bib0009","doi-asserted-by":"crossref","first-page":"737.e17","DOI":"10.1016\/j.urolonc.2020.04.010","article-title":"Association between metabolic syndrome and recurrence of non-muscle-invasive bladder cancer in older adults","volume":"38","author":"Garg","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0010","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2022050","article-title":"The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies","volume":"44","author":"Ahmadinezhad","year":"2022","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0011","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.2147\/CMAR.S181178","article-title":"The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97795299 subjects","volume":"10","author":"Peng","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.008_bib0012","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/ijc.25521","article-title":"Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can)","volume":"128","author":"H\u00e4ggstr\u00f6m","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.008_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.urpr.2017.02.012","article-title":"Association between metabolic syndrome and recurrence of nonmuscle invasive bladder cancer following bacillus Calmette-Gu\u00e9rin treatment","volume":"5","author":"Lenis","year":"2018","journal-title":"Urol Pr"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.008_bib0014","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.juro.2013.01.089","article-title":"Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder","volume":"190","author":"Kluth","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0015","unstructured":"National Kidney Foundation. Stages of Chronic Kidney Disease (CKD). Accessed September 29, 2024. https:\/\/www.kidney.org\/kidney-topics\/stages-chronic-kidney-disease-ckd"},{"issue":"17","key":"10.1016\/j.urolonc.2025.02.008_bib0016","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the Metabolic Syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.008_bib0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/iju.12644","article-title":"Association between metabolic syndrome obesity diabetes mellitus and oncological outcomes of bladder cancer: a systematic review","volume":"22","author":"Francesco","year":"2015","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.008_bib0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03009734.2018.1473534","article-title":"Positive association between hypertension and urinary bladder cancer: epidemiologic evidence involving 79236 propensity score-matched individuals","volume":"123","author":"Kok","year":"2018","journal-title":"Ups J Med Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2025.02.008_bib0019","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.urolonc.2025.02.008_bib0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0021","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","article-title":"Prognostic value of renin\u2013angiotensin system blockade in non-muscle-invasive bladder cancer","volume":"19","author":"Kazuyuki","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.urolonc.2025.02.008_bib0022","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2019.0463","article-title":"The surprisingly positive association between obesity and cancer immunotherapy efficacy","volume":"321","author":"Murphy","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.semcancer.2023.07.004","article-title":"Multifaceted effects of obesity on cancer immunotherapies: bridging preclinical models and clinical data","volume":"95","author":"Vick","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02404-x","article-title":"Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"18","author":"An","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.008_bib0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euf.2019.04.021","article-title":"Androgen suppression therapy is associated with lower recurrence of non\u2013muscle-invasive bladder cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.008_bib0026","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.008_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.008_bib0028","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.euo.2024.01.011","article-title":"Association of age with non\u2013muscle-invasive bladder cancer: unearthing a biological basis for epidemiological disparities?","volume":"7","author":"Lobo","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.008_bib0029","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-022-00611-3","article-title":"Bladder cancer inflammageing and microbiomes","volume":"19","author":"Martin","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.008_bib0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.it.2016.03.005","article-title":"Aging: a temporal dimension for neutrophils","volume":"37","author":"Adrover","year":"2016","journal-title":"Trends Immunol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:06:18Z","timestamp":1752602778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1078143925000328"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of metabolic syndrome and chronic kidney disease with nonmuscle invasive bladder cancer recurrence and progression","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}